Burger King is planning for a customer who still wants fast food, just less of it

Burger King is testing Whopper Bites and protein-forward bowls to hold onto a customer who wants fast food in smaller amounts, according to its president for the U.S. and Canada. A July Gallup poll put 11% of U.S. adults currently on a GLP-1 medication, nearly four times the share of two years ago.

Surveys are where the evidence sits for now. Nearly half of GLP-1 users told the National Restaurant Association they had cut back on dining out, and an April survey of 300 users by the equity research firm William Blair found 72% cutting back specifically on hamburgers. JPMorgan estimated in February that GLP-1s could erase between $30 billion and $55 billion in annual food and beverage revenue by as early as 2030.

None of that has reached the register yet. Comparable U.S. store sales rose 5.8% in the first quarter against a 1.1% drop a year earlier, and the executive is blunt that convenience, flavor and value are not going anywhere. That does not mean the surveys are wrong, only that a stated intention and a receipt are different objects.

The harder question is about culture rather than cuisine: what happens to a business built on abundance and value when a country eats fewer calories and protein becomes what people shop for. Simplicity is king in fast food, the executive says, which is why the chain wants demand to show up before it complicates the menu.

Read the full story at NBC News ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.